Target intelligence / Profile preview

Succinate dehydrogenase complex flavoprotein subunit A (SDHA)

Target
SDHA
Molecular classification
Enzyme, Mitochondrial protein, Component of electron transport chain (Complex II)
01

Overview

Succinate dehydrogenase complex flavoprotein subunit A (SDHA) is the major catalytic subunit of succinate-ubiquinone oxidoreductase (complex II of the mitochondrial respiratory chain). SDHA catalyzes the oxidation of succinate to fumarate in the citric acid (Krebs) cycle and transfers electrons to the electron transport chain, playing a crucial role in cellular energy metabolism. SDHA also participates in cell signaling as a tumor suppressor and as a regulator of the hypoxia-inducible factor (HIF) pathway by controlling succinate levels. Germline or somatic mutations in SDHA are associated with several cancers, most notably SDH-deficient gastrointestinal stromal tumors and paragangliomas, as well as metabolic and neurodegenerative disorders such as Leigh syndrome[1][2][3][4].

Other names
SDHAFlavoprotein subunit of complex IIFPSDH1SDH2SDHFSuccinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrialSuccinate dehydrogenase complex, subunit A, flavoprotein (Fp)CMD1GGMC2DN1PGL5PPGL5NDAXOAMalate dehydrogenase [quinone] flavoprotein subunit
02

Mechanism of action

Small molecules or mutations can inhibit SDHA, causing succinate accumulation, impaired electron transport, and HIF stabilization, which contribute to tumorigenesis[1].

03

Biological functions

Mitochondrial electron transportEnergy metabolism (oxidative phosphorylation, citric acid cycle)Tumor suppressionCellular oxygen sensingRegulation of hypoxia-inducible factor (HIF) pathway
04

Disease associations

Cancer (e.g., gastrointestinal stromal tumors, paraganglioma, pheochromocytoma)Neurodegeneration (Leigh syndrome)Hereditary syndromes (Carney triad, Carney-Stratakis syndrome)
05

Safety considerations

SDHA inhibition can disrupt cellular energy production and increase risk for severe metabolic dysfunction.Targeting SDHA may risk off-target toxicity to healthy tissues reliant on mitochondrial energy metabolism.Loss-of-function mutations are linked to tumor development and neurological disease in children[1].
06

Interacting drugs

There are no well-established, direct small molecule drugs that specifically target SDHA in clinical use; however, some experimental SDH inhibitors and metabolic drugs impact SDH activity in research settings.
07

Biomarkers

SDHA deficiency by immunohistochemistry or genetic testing (for predicting or diagnosing SDH-deficient tumors)[1].Succinate accumulation in tumors as a metabolic biomarker

Beyond the preview

Go deeper on Succinate dehydrogenase complex flavoprotein subunit A (SDHA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Succinate dehydrogenase complex flavoprotein subunit A (SDHA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call